228 related articles for article (PubMed ID: 22278420)
1. Serum TSH and risk of papillary thyroid cancer in nodular thyroid disease.
Fiore E; Vitti P
J Clin Endocrinol Metab; 2012 Apr; 97(4):1134-45. PubMed ID: 22278420
[TBL] [Abstract][Full Text] [Related]
2. Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role.
Fiore E; Rago T; Provenzale MA; Scutari M; Ugolini C; Basolo F; Di Coscio G; Berti P; Grasso L; Elisei R; Pinchera A; Vitti P
Endocr Relat Cancer; 2009 Dec; 16(4):1251-60. PubMed ID: 19528244
[TBL] [Abstract][Full Text] [Related]
3. L-thyroxine-treated patients with nodular goiter have lower serum TSH and lower frequency of papillary thyroid cancer: results of a cross-sectional study on 27 914 patients.
Fiore E; Rago T; Provenzale MA; Scutari M; Ugolini C; Basolo F; Di Coscio G; Miccoli P; Grasso L; Pinchera A; Vitti P
Endocr Relat Cancer; 2010 Mar; 17(1):231-9. PubMed ID: 20167722
[TBL] [Abstract][Full Text] [Related]
4. Hashimoto's thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with L-thyroxine.
Fiore E; Rago T; Latrofa F; Provenzale MA; Piaggi P; Delitala A; Scutari M; Basolo F; Di Coscio G; Grasso L; Pinchera A; Vitti P
Endocr Relat Cancer; 2011 Aug; 18(4):429-37. PubMed ID: 21565972
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological correlation of serum TSH in patients with thyroid nodule.
Mondal HP; Sen S; Sasmal S; Ghosal PK; Mukhopadhyay SK; Mukhopadhyay M
J Indian Med Assoc; 2011 May; 109(5):330, 335, 338. PubMed ID: 22187768
[TBL] [Abstract][Full Text] [Related]
6. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry.
Cooper DS; Specker B; Ho M; Sperling M; Ladenson PW; Ross DS; Ain KB; Bigos ST; Brierley JD; Haugen BR; Klein I; Robbins J; Sherman SI; Taylor T; Maxon HR
Thyroid; 1998 Sep; 8(9):737-44. PubMed ID: 9777742
[TBL] [Abstract][Full Text] [Related]
7. Lack of association between high serum thyroid-stimulating hormone level and risk of papillary thyroid microcarcinomas.
Sohn SY; Kim HJ; Jang HW; Kim SW; Chung JH
Head Neck; 2014 Jan; 36(1):43-6. PubMed ID: 23728859
[TBL] [Abstract][Full Text] [Related]
8. Thyrotropin serum concentrations in patients with papillary thyroid microcancers.
Gerschpacher M; Göbl C; Anderwald C; Gessl A; Krebs M
Thyroid; 2010 Apr; 20(4):389-92. PubMed ID: 20210672
[TBL] [Abstract][Full Text] [Related]
9. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage.
Haymart MR; Repplinger DJ; Leverson GE; Elson DF; Sippel RS; Jaume JC; Chen H
J Clin Endocrinol Metab; 2008 Mar; 93(3):809-14. PubMed ID: 18160464
[TBL] [Abstract][Full Text] [Related]
10. [Association between preoperative serum thyroid-stimulating hormone level and nonfunctioning malignant nodule thyroid disease].
Zeng Q; Liu J; Zhu J; Hu G
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 Dec; 28(24):1931-3. PubMed ID: 25895308
[TBL] [Abstract][Full Text] [Related]
11. Association between preoperative thyrotrophin and clinicopathological and aggressive features of papillary thyroid cancer.
Tam AA; Ozdemir D; Aydın C; Bestepe N; Ulusoy S; Sungu N; Ersoy R; Cakir B
Endocrine; 2018 Mar; 59(3):565-572. PubMed ID: 29374347
[TBL] [Abstract][Full Text] [Related]
12. Preoperative TSH level and risk of thyroid cancer in patients with nodular thyroid disease: nodule size contribution.
Zafón C; Obiols G; Mesa J
Endocrinol Nutr; 2015 Jan; 62(1):24-8. PubMed ID: 25066642
[TBL] [Abstract][Full Text] [Related]
13. Hashimoto's thyroiditis as a risk factor of papillary thyroid cancer may improve cancer prognosis.
Lun Y; Wu X; Xia Q; Han Y; Zhang X; Liu Z; Wang F; Duan Z; Xin S; Zhang J
Otolaryngol Head Neck Surg; 2013 Mar; 148(3):396-402. PubMed ID: 23300224
[TBL] [Abstract][Full Text] [Related]
14. The association between serum TSH concentration and thyroid cancer.
Boelaert K
Endocr Relat Cancer; 2009 Dec; 16(4):1065-72. PubMed ID: 19620248
[TBL] [Abstract][Full Text] [Related]
15. Effects on bone mineral density by treatment of benign nodular goiter with mildly suppressive doses of L-thyroxine in a cohort women study.
Appetecchia M
Horm Res; 2005; 64(6):293-8. PubMed ID: 16269872
[TBL] [Abstract][Full Text] [Related]
16. [Increase in TSH levels in thyroid carcinoma patients after withdrawal of suppressive levothyroxine medication].
Hackländer S; Voth E; Schicha H
Nuklearmedizin; 1996 Oct; 35(5):170-4. PubMed ID: 9005413
[TBL] [Abstract][Full Text] [Related]
17. 'Incidental' and 'non-incidental' thyroid papillary microcarcinomas are two different entities.
Provenzale MA; Fiore E; Ugolini C; Torregrossa L; Morganti R; Molinaro E; Miccoli P; Basolo F; Vitti P
Eur J Endocrinol; 2016 Jun; 174(6):813-20. PubMed ID: 27032694
[TBL] [Abstract][Full Text] [Related]
18. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration.
Boelaert K; Horacek J; Holder RL; Watkinson JC; Sheppard MC; Franklyn JA
J Clin Endocrinol Metab; 2006 Nov; 91(11):4295-301. PubMed ID: 16868053
[TBL] [Abstract][Full Text] [Related]
19. Male sex, single nodularity, and young age are associated with the risk of finding a papillary thyroid cancer on fine-needle aspiration cytology in a large series of patients with nodular thyroid disease.
Rago T; Fiore E; Scutari M; Santini F; Di Coscio G; Romani R; Piaggi P; Ugolini C; Basolo F; Miccoli P; Pinchera A; Vitti P
Eur J Endocrinol; 2010 Apr; 162(4):763-70. PubMed ID: 20083557
[TBL] [Abstract][Full Text] [Related]
20. Both thyroid autoimmunity and increased serum TSH are independent risk factors for malignancy in patients with thyroid nodules.
Boi F; Minerba L; Lai ML; Marziani B; Figus B; Spanu F; Borghero A; Mariotti S
J Endocrinol Invest; 2013 May; 36(5):313-20. PubMed ID: 22931861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
